LMP Capital and Income Fund Inc.
SCD
Updated: 23/09/2026, 15:57:11
The LMP Capital and Income Fund Inc. operates as a closed-end balanced mutual fund, primarily overseen by Legg Mason Partners Fund Advisor, LLC. Additional management responsibilities are shared with Clearbridge Investments, LLC, Western Asset Management Company Limited, and Western Asset Management Company. Its investment mandate extends globally, encompassing both public equity and fixed-income securities from businesses spanning various sectors. Key holdings include shares of large-capitalization firms, corporate bonds and notes of intermediate maturity with a minimum A- rating, both energy and non-energy master limited partnerships (MLPs), and real estate investment trusts (REITs). Portfolio construction is heavily influenced by a rigorous analysis of economic, market, and political landscapes, as well as fiscal and monetary policies, alongside thorough security valuation. Its performance is measured against two standard benchmarks: the U.S. Aggregate Index and the S&P 500 Index. Established in the United States on November 12, 2003, it was previously recognized as the Salomon Brothers Capital and Income Fund Inc.
No summaries found.
- Share price
- $15.03
- Market cap
- $5.03B
- Exchange
- NYSE
- Currency
- USD
- CEO
- Kenneth Donald Fuller
- Employees
- N/A
- IPO date
- 25/02/2004
- Beta
- 0.969
- Last dividend
- $0.00
- Day range
- $15.00 – $15.07
- 52-week range
- $13.79 – $16.18
- 1-day performance
- -1.15%
- 1-year performance
- 8.96%
- Current drawdown (1Y)
- -7.14%
- CIK
- 0001270131
- CUSIP
- 50208A102
- ISIN
- US50208A1025
- Created
- 07/12/2025, 14:08:10
- Last update
- 23/09/2026, 15:57:11
Track LMP Capital and Income Fund Inc. with an AI analyst
See which prediction-market events move SCD, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
PRNewsWire • STOCK • 14/04/2026, 09:30:00
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
PRNewsWire • STOCK • 09/04/2026, 09:30:00
SCD: Unique CEF Could Be Well-Positioned To Outperform In The Current Environment
Seeking Alpha • STOCK • 07/04/2026, 14:20:21
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
GlobeNewsWire • STOCK • 01/04/2026, 19:12:00
SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026
GlobeNewsWire • STOCK • 30/03/2026, 10:20:00
Scandium Canada Announces $10 Million Bought Deal Life Offering of Units
Newsfile Corp • STOCK • 03/03/2026, 17:45:00
SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)
GlobeNewsWire • STOCK • 09/02/2026, 09:20:00